Drugs / REGEND007
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT07355868 | Mar → Oct 2026 expected | chronic obstructive pulmonary disease | Regend Therapeutics | Recruiting | No outcome recorded |
| Phase 0 | NCT07359963 | Feb 2026 → Feb 2027 expected | idiopathic pulmonary fibrosis | Regend Therapeutics | Not yet recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REGEND007 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07355868 ↗ |
| Modality | Cell therapy | “REGEND007 cell therapy” NCT07355868 ↗ |
| Route | Intravenous | “REGEND007 cell therapy administered by intravenous infusion” NCT07355868 ↗ |